Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.31
- Piotroski Score 4.00
- Grade Buy
- Symbol (EBS)
- Company Emergent BioSolutions Inc.
- Price $11.02
- Changes Percentage (19.78%)
- Change $1.82
- Day Low $10.98
- Day High $12.73
- Year High $15.10
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $51.50
- High Stock Price Target $65.00
- Low Stock Price Target $38.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$10.97
- Trailing P/E Ratio -0.56
- Forward P/E Ratio -0.56
- P/E Growth -0.56
- Net Income $-760,500,000
Income Statement
Quarterly
Annual
Latest News of EBS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
20 Stunning Wix Website Examples
Discover visually appealing and unique Wix websites across various industries, including captivating restaurant sites like Chef Jean-François Bury's dynamic design, Yang's Place vibrant imagery, Kare...
By Forbes | 1 day ago -
Transcript: David Becker, Samantha Vinograd and Chris Krebs on "Face the Nation with Margaret Brennan," Nov. 3, 2024
In an interview on "Face the Nation," experts discussed election security threats, including foreign disinformation tactics, influence operations by Iran and Russia, and the importance of relying on o...
By CBS News | 4 days ago -
Thousands Pack Dublin Streets for Fake Halloween Parade Listed on AI Website
Thousands in Dublin expecting a Halloween parade were misled by MySpiritHalloween.com, causing confusion and disappointment. The event was falsely listed on the site, leading to a crowd gathering with...
By PEOPLE.com | 6 days ago
